You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBuprenorphine
Accession NumberDB00921  (APRD00670)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational, Vet Approved
DescriptionBuprenorphine is a derivative of the opioid alkaloid thebaine that is a more potent (25 - 40 times) and longer lasting analgesic than morphine. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. [PubChem]
Structure
Thumb
Synonyms
(-)-Buprenorphine
(−)-buprenorphine
17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol
2-[3-Cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
21-Cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
Buprenophine
Buprenorfina
Buprenorphinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Belbucafilm750 ug/1buccalEndo Pharmaceuticals2015-06-01Not applicableUs
Belbucafilm150 ug/1buccalEndo Pharmaceuticals2015-06-01Not applicableUs
Belbucafilm900 ug/1buccalEndo Pharmaceuticals2015-06-01Not applicableUs
Belbucafilm300 ug/1buccalEndo Pharmaceuticals2015-06-01Not applicableUs
Belbucafilm450 ug/1buccalEndo Pharmaceuticals2015-06-01Not applicableUs
Belbucafilm75 ug/1buccalEndo Pharmaceuticals2015-06-01Not applicableUs
Belbucafilm600 ug/1buccalEndo Pharmaceuticals2015-06-01Not applicableUs
Buprenexinjection.3 mg/mLintramuscular; intravenousIndivior Inc.1985-06-30Not applicableUs
Butranspatch, extended release20 ug/htransdermalPurdue Pharma LP2011-02-14Not applicableUs
Butranspatch, extended release10 ug/htransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-26Not applicableUs
Butranspatch, extended release20 ug/htransdermalA S Medication Solutions Llc2011-02-14Not applicableUs
Butranspatch, extended release7.5 ug/htransdermalPurdue Pharma LP2011-02-14Not applicableUs
Butranspatch, extended release20 ug/htransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-26Not applicableUs
Butranspatch, extended release5 ug/htransdermalPurdue Pharma LP2011-02-14Not applicableUs
Butranspatch, extended release15 ug/htransdermalPurdue Pharma LP2011-02-14Not applicableUs
Butranspatch, extended release5 ug/htransdermalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-26Not applicableUs
Butranspatch, extended release10 ug/htransdermalPurdue Pharma LP2011-02-14Not applicableUs
Butranspatch, extended release10 ug/htransdermalA S Medication Solutions Llc2011-02-14Not applicableUs
Butrans 10patch10 mcgtransdermalPurdue Pharma2010-05-26Not applicableCanada
Butrans 15patch15 mcgtransdermalPurdue Pharma2016-06-15Not applicableCanada
Butrans 20patch20 mcgtransdermalPurdue Pharma2010-05-26Not applicableCanada
Butrans 5patch5 mcgtransdermalPurdue Pharma2010-05-26Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Buprenorphinetablet2 mg/1sublingualTeva Pharmaceuticals Usa, Inc.2010-05-25Not applicableUs
Buprenorphinetablet2 mg/1sublingualSun Pharmaceutical Industries Limited2016-02-17Not applicableUs
Buprenorphinetablet8 mg/1sublingualTeva Pharmaceuticals Usa, Inc.2010-05-25Not applicableUs
Buprenorphinetablet8 mg/1sublingualSun Pharmaceutical Industries Limited2016-02-17Not applicableUs
Buprenorphinetablet8 mg/1sublingualActavis Pharma, Inc.2015-03-23Not applicableUs
Buprenorphinetablet2 mg/1sublingualActavis Pharma, Inc.2015-03-23Not applicableUs
Buprenorphine HCltablet2 mg/1sublingualRoxane Laboratories, Inc2009-10-08Not applicableUs
Buprenorphine HCltablet8 mg/1sublingualRoxane Laboratories, Inc2009-10-08Not applicableUs
Buprenorphine HCltablet2 mg/1sublingualCardinal Health2009-10-08Not applicableUs
Buprenorphine Hydrochlorideinjection, solution.324 mg/mLintramuscular; intravenousAmerican Regent, Inc.2010-08-13Not applicableUs
Buprenorphine Hydrochloridetablet2 mg/1sublingualREMEDYREPACK INC.2013-07-25Not applicableUs
Buprenorphine Hydrochloridetablet2 mg/1oralREMEDYREPACK INC.2010-12-07Not applicableUs
Buprenorphine Hydrochlorideinjection, solution.3 mg/mLintramuscular; intravenousRebel Distributors Corp2010-07-12Not applicableUs
Buprenorphine Hydrochloridetablet8 mg/1sublingualA S Medication Solutions Llc2010-09-24Not applicableUs
Buprenorphine Hydrochloridetablet2 mg/1sublingualHi Tech Pharmacal Co., Inc.2010-09-24Not applicableUs
Buprenorphine Hydrochlorideinjection.324 mg/mLintramuscular; intravenousPar Pharmaceutical Inc.2015-07-30Not applicableUs
Buprenorphine Hydrochloridetablet8 mg/1sublingualHi Tech Pharmacal Co., Inc.2010-09-24Not applicableUs
Buprenorphine Hydrochloridetablet8 mg/1sublingualPd Rx Pharmaceuticals, Inc.2010-09-24Not applicableUs
Buprenorphine Hydrochlorideinjection, solution.3 mg/mLintramuscular; intravenousHospira, Inc.2010-07-12Not applicableUs
Buprenorphine Hydrochloridetablet2 mg/1oralREMEDYREPACK INC.2010-12-07Not applicableUs
Buprenorphine Hydrochloridetablet8 mg/1oralbryant ranch prepack2009-10-09Not applicableUs
Buprenorphine Hydrochloridetablet8 mg/1sublingualREMEDYREPACK INC.2013-06-24Not applicableUs
Buprenorphine Hydrochloride Sublingualtablet2 mg/1sublingualMylan Pharmaceuticals Inc.2015-03-06Not applicableUs
Buprenorphine Hydrochloride Sublingualtablet8 mg/1sublingualMylan Pharmaceuticals Inc.2015-03-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AddnokRusan Pharma Ltd.
BuprelNot Available
BuprigesicNeon Laboratories
MorgesicSamarth Pharma
NorphinUnichem Laboratories
NorspanNot Available
ProbuphineTitan Pharmaceuticals, Inc.
SubutexNot Available
TemgesicNot Available
TidigesicSun Pharmaceuticals
Brand mixtures
NameLabellerIngredients
Act Buprenorphine/naloxoneActavis Pharma Company
BunavailBio Delivery Sciences International, Inc.
Buprenorphine and NaloxoneTeva Pharmaceuticals USA Inc
Buprenorphine HCl and Naloxone HClMallinckrodt, Inc.
Buprenorphine Hydrochloride and Naloxone Hydrochloride DihydrateRoxane Laboratories, Inc.
Mylan-buprenorphine/naloxoneMylan Pharmaceuticals Ulc
SuboxoneIndivior Inc.
Teva-buprenorphine/naloxoneTeva Canada Limited
ZubsolvOrexo Us, Inc.
Salts
Name/CASStructureProperties
Buprenorphine Hydrochloride
53152-21-9
Thumb
  • InChI Key: UAIXRPCCYXNJMQ-RZIPZOSSSA-N
  • Monoisotopic Mass: 503.280236544
  • Average Mass: 504.101
DBSALT000019
Categories
UNII40D3SCR4GZ
CAS number52485-79-7
WeightAverage: 467.6401
Monoisotopic: 467.303558805
Chemical FormulaC29H41NO4
InChI KeyInChIKey=RMRJXGBAOAMLHD-IHFGGWKQSA-N
InChI
InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
IUPAC Name
(1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11-trien-11-ol
SMILES
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[[email protected]]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Azaspirodecane
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.
PharmacodynamicsBuprenorphine is a synthetic opioid analgesic and thebaine derivative, with a longer duration of action than morphine. Buprenorphine interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, buprenorphine exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Buprenorphine may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Buprenorphine depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Pharmacological effects peaks at 15 minutes and persists for 6 hours or longer when given intramuscularly. When given intravenously, the time to onset and peak effect are shortened.
Mechanism of actionBuprenorphine's analgesic effect is due to partial agonist activity at mu-opioid receptors. Buprenorphine is also a kappa-opioid receptor antagonist. The partial agonist activity means that opioid receptor antagonists (e.g., an antidote such as naloxone) only partially reverse the effects of buprenorphine. The binding to the mu and kappa receptors results in hyperpolarization and reduced neuronal excitability. Furthermore, buprenorphine slowly dissociates from its receptor. This observation would account for the longer duration of action compared to morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence. Its receptor fixation half life is 40 minutes which is significantly longer than morphine (milliseconds).
Related Articles
Absorption31% bioavailability (sublingual). Sublingual absorption is also dependent on pH. The length of time the tablet is under the tongue has little effect on absorption. Although buprenorphine is rapidly absorbed from the oral mucosa, the absorption into the systemic is slower. The time to reach peak plasma concentration (Tmax) varies between individuals (range of 40 minutes to 3.5 hours). How buprenorphine is formulated does not affect this pharmacokinetic parameter. It also undergoes extensive first-pass metabolism and as a consequence, has very low oral bioavailability. Coadministration with naloxone does not effect the pharmacokinetics of buprenorphine.
Volume of distribution

Buprenorphine is very lipophillic and is thus highly distributed. The estimated volume of distribution is 188 – 335 L when given intravenously. It is able to cross into the placenta and breast milk.

Protein binding96% protein bound to alpha- and beta-globulin.
Metabolism

Hepatic. Buprenorphine undergoes both N-dealkylation to norbuprenorphine and glucuronidation. The N-dealkylation pathway is mediated by cytochrome P-450 3A4 isozyme. Norbuprenorphine, an active metabolite and has one-fifth of the pharmacologic activity of the parent compound, can further undergo glucuronidation.

SubstrateEnzymesProduct
Buprenorphine
NorbuprenorphineDetails
Buprenorphine
HydroxybuprenorphineDetails
Buprenorphine
Buprenorphine glucuronideDetails
Norbuprenorphine
Not Available
HydroxynorbuprenorphineDetails
Hydroxybuprenorphine
Not Available
HydroxynorbuprenorphineDetails
Route of eliminationBuprenorphine, like morphine and other phenolic opioid analgesics, is metabolized by the liver and its clearance is related to hepatic blood flow. It is primarily eliminated via feces (as free forms of buprenorphine and norbuprenorphine) while 10 - 30% of the dose is excreted in urine (as conjugated forms of buprenorphine and norbuprenorphine).
Half lifeIV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours); Sublingual administration = 37 hours.
Clearance

Clearance may be higher in children than in adults.
Plasma clearance rate, IV administration, anaesthetized patients = 901.2 ± 39.7 mL/min;
Plasma clearance rate, IV administration, healthy subjects = 1042 – 1280 mL/min.

ToxicityManifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression and death.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Buprenorphine Action PathwayDrug actionSMP00684
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9055
Blood Brain Barrier+0.9401
Caco-2 permeable+0.6893
P-glycoprotein substrateSubstrate0.9126
P-glycoprotein inhibitor IInhibitor0.5192
P-glycoprotein inhibitor IINon-inhibitor0.6992
Renal organic cation transporterInhibitor0.5797
CYP450 2C9 substrateNon-substrate0.8366
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.8142
CYP450 1A2 substrateNon-inhibitor0.9153
CYP450 2C9 inhibitorNon-inhibitor0.8692
CYP450 2D6 inhibitorNon-inhibitor0.6721
CYP450 2C19 inhibitorNon-inhibitor0.7801
CYP450 3A4 inhibitorNon-inhibitor0.8322
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9212
Ames testNon AMES toxic0.7448
CarcinogenicityNon-carcinogens0.9391
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1511 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Non-inhibitor0.586
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Purdue pharma lp
  • Reckitt benckiser pharmaceuticals inc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Pharmaforce inc
  • Barr laboratories inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
Filmbuccal150 ug/1
Filmbuccal300 ug/1
Filmbuccal450 ug/1
Filmbuccal600 ug/1
Filmbuccal75 ug/1
Filmbuccal750 ug/1
Filmbuccal900 ug/1
Filmbuccal
Injectionintramuscular; intravenous.3 mg/mL
Tabletsublingual2 mg/1
Tabletsublingual8 mg/1
Injectionintramuscular; intravenous.324 mg/mL
Injection, solutionintramuscular; intravenous.3 mg/mL
Injection, solutionintramuscular; intravenous.324 mg/mL
Tabletoral2 mg/1
Tabletoral8 mg/1
Tabletsublingual
Patch, extended releasetransdermal10 ug/h
Patch, extended releasetransdermal15 ug/h
Patch, extended releasetransdermal20 ug/h
Patch, extended releasetransdermal5 ug/h
Patch, extended releasetransdermal7.5 ug/h
Patchtransdermal10 mcg
Patchtransdermal15 mcg
Patchtransdermal20 mcg
Patchtransdermal5 mcg
Film, solublebuccal; sublingual
Film, solublesublingual
Tabletoral
Tablet, orally disintegratingsublingual
Prices
Unit descriptionCostUnit
Buprenex 0.3 mg/ml Solution (1 Box Contains Five 1ml Box)46.39USD box
Subutex 8 mg Sublingual Tabs10.2USD tab
Subutex 8 mg tablet sl9.4USD tablet
Buprenorphine 8 mg tablet sl7.74USD tablet
Buprenex 0.3 mg/ml ampul6.96USD ml
Subutex 2 mg Sublingual Tabs5.59USD tab
Subutex 2 mg tablet sl5.0USD tablet
Buprenorphine 2 mg tablet sl4.14USD tablet
Buprenorphine 0.3 mg/ml vial2.96USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2030178 No1995-08-152010-11-16Canada
CA2276170 No2007-12-042018-02-24Canada
US5240711 No1993-11-282010-11-28Us
US5968547 No1997-09-292017-09-29Us
US6159498 No1996-10-182016-10-18Us
US6264980 No1995-12-182015-12-18Us
US6344211 No1995-12-182015-12-18Us
US7579019 No2000-01-222020-01-22Us
US8017150 No2003-02-132023-02-13Us
US8147866 No2007-07-232027-07-23Us
US8454996 No1999-09-242019-09-24Us
US8470361 No2010-05-222030-05-22Us
US8475832 No2010-03-262030-03-26Us
US8603514 No2004-04-032024-04-03Us
US8658198 No2007-12-032027-12-03Us
US8703177 No2012-08-202032-08-20Us
US8940330 No2012-09-182032-09-18Us
US9259421 No2012-09-182032-09-18Us
USRE41408 No1997-09-292017-09-29Us
USRE41489 No1997-09-292017-09-29Us
USRE41571 No1997-09-292017-09-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.98AVDEEF,A ET AL. (1996)
pKa8.31 (at 25 °C)AVDEEF,A ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0168 mg/mLALOGPS
logP4.53ALOGPS
logP3.55ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)7.5ChemAxon
pKa (Strongest Basic)12.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.16 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity131.76 m3·mol-1ChemAxon
Polarizability53.11 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Kazuhisa Ninomiya, Yasuhiro Fukushima, Mutsuo Okumura, Yuko Hosokawa, “Buprenorphine percutaneous absorption preparation.” U.S. Patent US6090405, issued August, 1992.

US6090405
General References
  1. Huang P, Kehner GB, Cowan A, Liu-Chen LY: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001 May;297(2):688-95. [PubMed:11303059 ]
  2. Bodkin JA, Zornberg GL, Lukas SE, Cole JO: Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995 Feb;15(1):49-57. [PubMed:7714228 ]
  3. Elkader A, Sproule B: Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661-80. [PubMed:15966752 ]
External Links
ATC CodesN02AE01N07BC01N07BC51
AHFS Codes
  • 28:08.12
PDB EntriesNot Available
FDA labelDownload (345 KB)
MSDSDownload (196 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Buprenorphine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Buprenorphine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Buprenorphine is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Buprenorphine is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe serum concentration of Buprenorphine can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Buprenorphine.
AcepromazineAcepromazine may increase the hypotensive activities of Buprenorphine.
AcepromazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Buprenorphine.
AcetazolamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Acetazolamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Buprenorphine.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Buprenorphine.
adipiplonThe risk or severity of adverse effects can be increased when Buprenorphine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Buprenorphine.
AgomelatineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Buprenorphine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Alfaxalone.
AlfentanilBuprenorphine may decrease the analgesic activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Buprenorphine.
AlimemazineAlimemazine may increase the hypotensive activities of Buprenorphine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Buprenorphine.
AlphacetylmethadolBuprenorphine may decrease the analgesic activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Buprenorphine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Buprenorphine.
AlvimopanThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Alvimopan.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Buprenorphine.
AmilorideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Amiloride.
AmiodaroneThe metabolism of Buprenorphine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Buprenorphine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Buprenorphine.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Buprenorphine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Amobarbital.
AmoxapineBuprenorphine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Buprenorphine.
AmperozideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Buprenorphine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Buprenorphine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Buprenorphine.
AprepitantThe serum concentration of Buprenorphine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Buprenorphine.
ArtemetherThe metabolism of Buprenorphine can be decreased when combined with Artemether.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Buprenorphine resulting in a loss in efficacy.
ArticaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Asenapine.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Buprenorphine.
AtazanavirThe metabolism of Buprenorphine can be decreased when combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Buprenorphine.
AtomoxetineThe metabolism of Buprenorphine can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Buprenorphine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Buprenorphine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Buprenorphine.
AzaperoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Azaperone.
AzelastineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Buprenorphine.
AzosemideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Buprenorphine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Benmoxin.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Buprenorphine.
BenzocaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Buprenorphine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Buprenorphine.
BetaxololThe metabolism of Buprenorphine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Buprenorphine can be decreased when it is combined with Bexarotene.
BezitramideBuprenorphine may decrease the analgesic activities of Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Buprenorphine.
BoceprevirThe serum concentration of Buprenorphine can be decreased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Buprenorphine.
BortezomibThe metabolism of Buprenorphine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Buprenorphine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Buprenorphine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buprenorphine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BrimonidineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Buprenorphine.
BrompheniramineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Buprenorphine.
BupropionThe metabolism of Buprenorphine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Buprenorphine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Buprenorphine.
ButacaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Buprenorphine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Buprenorphine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Buprenorphine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Buprenorphine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Buprenorphine.
Canrenoic acidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Canrenoic acid.
CapecitabineThe metabolism of Buprenorphine can be decreased when combined with Capecitabine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Buprenorphine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Buprenorphine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Carbinoxamine.
CarfentanilBuprenorphine may decrease the analgesic activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Buprenorphine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Buprenorphine.
CarisoprodolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Caroxazone.
CelecoxibThe metabolism of Buprenorphine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Buprenorphine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Buprenorphine.
CetirizineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Buprenorphine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chloroprocaine.
ChloroquineThe metabolism of Buprenorphine can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Buprenorphine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Buprenorphine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Buprenorphine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Buprenorphine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Buprenorphine can be decreased when combined with Cholecalciferol.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Buprenorphine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Buprenorphine.
CimetidineThe metabolism of Buprenorphine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Buprenorphine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Buprenorphine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Buprenorphine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Buprenorphine.
CitalopramBuprenorphine may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Buprenorphine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Buprenorphine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Buprenorphine.
ClemastineThe metabolism of Buprenorphine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Buprenorphine.
ClobazamThe metabolism of Buprenorphine can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Buprenorphine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Buprenorphine.
ClomipramineBuprenorphine may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Buprenorphine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Buprenorphine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Buprenorphine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Buprenorphine.
ClopidogrelThe metabolism of Buprenorphine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Buprenorphine.
ClotrimazoleThe metabolism of Buprenorphine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Buprenorphine.
ClozapineThe metabolism of Buprenorphine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Buprenorphine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Buprenorphine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Buprenorphine.
CodeineBuprenorphine may decrease the analgesic activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Buprenorphine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Buprenorphine.
ConivaptanThe serum concentration of Buprenorphine can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Buprenorphine.
CrizotinibThe metabolism of Buprenorphine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Buprenorphine.
CyclizineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Buprenorphine.
CyclosporineThe metabolism of Buprenorphine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Buprenorphine.
CyclothiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Buprenorphine.
DabrafenibThe serum concentration of Buprenorphine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Buprenorphine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Buprenorphine.
DantroleneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Buprenorphine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Buprenorphine.
DapoxetineBuprenorphine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Buprenorphine.
DarunavirThe serum concentration of Buprenorphine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Buprenorphine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Buprenorphine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Buprenorphine.
DeferasiroxThe serum concentration of Buprenorphine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Buprenorphine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desflurane.
DesipramineThe metabolism of Buprenorphine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Buprenorphine.
DesmopressinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Detomidine.
DexamethasoneThe serum concentration of Buprenorphine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Buprenorphine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Buprenorphine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Buprenorphine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Buprenorphine.
DextromoramideBuprenorphine may decrease the analgesic activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Buprenorphine.
DextropropoxypheneBuprenorphine may decrease the analgesic activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Buprenorphine.
DezocineBuprenorphine may decrease the analgesic activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Buprenorphine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Buprenorphine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Buprenorphine.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Buprenorphine.
DifenoxinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Buprenorphine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Buprenorphine.
DihydrocodeineBuprenorphine may decrease the analgesic activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Buprenorphine.
DihydroergotamineThe metabolism of Buprenorphine can be decreased when combined with Dihydroergotamine.
DihydroetorphineBuprenorphine may decrease the analgesic activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Buprenorphine.
DihydromorphineBuprenorphine may decrease the analgesic activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Buprenorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Buprenorphine.
DiltiazemThe metabolism of Buprenorphine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Buprenorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Buprenorphine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Diphenhydramine.
DiphenoxylateBuprenorphine may decrease the analgesic activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Buprenorphine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Buprenorphine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Buprenorphine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Buprenorphine.
DoramectinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Buprenorphine.
DoxycyclineThe metabolism of Buprenorphine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
DoxylamineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Doxylamine.
DPDPEBuprenorphine may decrease the analgesic activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Buprenorphine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
DronedaroneThe metabolism of Buprenorphine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Buprenorphine.
DrospirenoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Drotebanol.
DuloxetineThe metabolism of Buprenorphine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Buprenorphine.
EcgonineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Buprenorphine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Buprenorphine.
EfavirenzThe serum concentration of the active metabolites of Buprenorphine can be reduced when Buprenorphine is used in combination with Efavirenz resulting in a loss in efficacy.
EfavirenzThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Buprenorphine.
EliglustatThe metabolism of Buprenorphine can be decreased when combined with Eliglustat.
EluxadolineBuprenorphine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Buprenorphine.
EntacaponeThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Entacapone.
EnzalutamideThe serum concentration of Buprenorphine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Buprenorphine.
EplerenoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Eplerenone.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Buprenorphine.
ErythromycinThe metabolism of Buprenorphine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Buprenorphine.
EscitalopramBuprenorphine may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Buprenorphine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Buprenorphine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Buprenorphine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Buprenorphine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Buprenorphine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid.
EthanolBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Buprenorphine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Buprenorphine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Buprenorphine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Buprenorphine.
EthosuximideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethyl loflazepate.
EthylmorphineBuprenorphine may decrease the analgesic activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Buprenorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Buprenorphine.
EtoperidoneBuprenorphine may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Buprenorphine.
EtorphineBuprenorphine may decrease the analgesic activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Buprenorphine.
EtravirineThe serum concentration of Buprenorphine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Buprenorphine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Buprenorphine.
EzogabineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Felbamate.
FelodipineThe metabolism of Buprenorphine can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fencamfamine.
FenfluramineBuprenorphine may increase the serotonergic activities of Fenfluramine.
FentanylBuprenorphine may decrease the analgesic activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Buprenorphine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Buprenorphine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Buprenorphine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Buprenorphine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Buprenorphine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Buprenorphine.
FlibanserinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Flibanserin.
FloxuridineThe metabolism of Buprenorphine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Buprenorphine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Flunitrazepam.
FluorouracilThe metabolism of Buprenorphine can be decreased when combined with Fluorouracil.
FluoxetineBuprenorphine may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Buprenorphine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Buprenorphine.
FluphenazineFluphenazine may increase the hypotensive activities of Buprenorphine.
FluphenazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Buprenorphine.
FluspirileneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Buprenorphine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Buprenorphine can be decreased when combined with Fluvastatin.
FluvoxamineBuprenorphine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Buprenorphine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Buprenorphine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Buprenorphine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fospropofol.
FurazolidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furazolidone.
FurosemideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide.
Fusidic AcidThe serum concentration of Buprenorphine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Buprenorphine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Buprenorphine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Buprenorphine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Buprenorphine.
GemfibrozilThe metabolism of Buprenorphine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Buprenorphine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Buprenorphine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Buprenorphine.
GuanfacineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Buprenorphine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Buprenorphine.
HaloperidolThe metabolism of Buprenorphine can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Halothane.
HeroinBuprenorphine may decrease the analgesic activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Buprenorphine.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Buprenorphine.
HexobarbitalThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Buprenorphine.
HydracarbazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydracarbazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydrochlorothiazide.
HydrocodoneBuprenorphine may decrease the analgesic activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Buprenorphine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Buprenorphine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydroflumethiazide.
HydromorphoneBuprenorphine may decrease the analgesic activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Buprenorphine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Buprenorphine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
HydroxyzineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Buprenorphine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Buprenorphine.
IdelalisibThe serum concentration of Buprenorphine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iloperidone.
ImatinibThe metabolism of Buprenorphine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Buprenorphine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Buprenorphine.
ImipramineThe metabolism of Buprenorphine can be decreased when combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Buprenorphine.
IndalpineBuprenorphine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Indapamide.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Buprenorphine.
IndinavirThe metabolism of Buprenorphine can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Buprenorphine.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Buprenorphine.
IproclozideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproniazid.
IrbesartanThe metabolism of Buprenorphine can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Buprenorphine.
IsavuconazoniumThe metabolism of Buprenorphine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Buprenorphine.
IsoniazidThe metabolism of Buprenorphine can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Isosorbide.
IsradipineThe metabolism of Buprenorphine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Buprenorphine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Buprenorphine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Buprenorphine.
KetamineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Buprenorphine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Buprenorphine.
KetobemidoneBuprenorphine may decrease the analgesic activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Buprenorphine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Buprenorphine.
KetoconazoleThe metabolism of Buprenorphine can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Buprenorphine is combined with KW-3902.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Buprenorphine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Buprenorphine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Buprenorphine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Buprenorphine.
LapatinibThe metabolism of Buprenorphine can be decreased when combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Buprenorphine.
LeflunomideThe metabolism of Buprenorphine can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Buprenorphine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Buprenorphine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Buprenorphine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Buprenorphine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Buprenorphine.
Levomethadyl AcetateBuprenorphine may decrease the analgesic activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Buprenorphine.
LevomilnacipranBuprenorphine may increase the serotonergic activities of Levomilnacipran.
LevorphanolBuprenorphine may decrease the analgesic activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Buprenorphine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Buprenorphine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Buprenorphine.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Buprenorphine.
LithiumThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Lithium.
LofentanilBuprenorphine may decrease the analgesic activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Buprenorphine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Buprenorphine.
LopinavirThe metabolism of Buprenorphine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Buprenorphine.
LorcaserinThe metabolism of Buprenorphine can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Buprenorphine.
LosartanThe metabolism of Buprenorphine can be decreased when combined with Losartan.
LovastatinThe metabolism of Buprenorphine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Buprenorphine.
Lu AA21004Buprenorphine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Buprenorphine.
LuliconazoleThe serum concentration of Buprenorphine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Buprenorphine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Buprenorphine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mebanazine.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine.
MeclizineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Buprenorphine.
MepivacaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Buprenorphine.
MersalylThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Buprenorphine.
MesoridazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Metaxalone.
MethadoneBuprenorphine may decrease the analgesic activities of Methadone.
MethadoneThe metabolism of Buprenorphine can be decreased when combined with Methadone.
Methadyl AcetateBuprenorphine may decrease the analgesic activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Buprenorphine.
MethamphetamineMethamphetamine may increase the analgesic activities of Buprenorphine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Buprenorphine.
MethapyrileneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Buprenorphine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Buprenorphine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Buprenorphine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methyclothiazide.
Methylene blueThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methylene blue.
Methylene blueMethylene blue may increase the hypotensive activities of Buprenorphine.
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Buprenorphine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Buprenorphine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Buprenorphine.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Buprenorphine.
MetolazoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Buprenorphine.
MetoprololThe metabolism of Buprenorphine can be decreased when combined with Metoprolol.
MetyrosineBuprenorphine may increase the sedative activities of Metyrosine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Buprenorphine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Buprenorphine.
MifepristoneThe metabolism of Buprenorphine can be decreased when combined with Mifepristone.
MilnacipranBuprenorphine may increase the serotonergic activities of Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Buprenorphine.
MirabegronThe metabolism of Buprenorphine can be decreased when combined with Mirabegron.
MirtazapineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Buprenorphine.
MitotaneThe serum concentration of Buprenorphine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Buprenorphine.
MoclobemideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Moclobemide.
ModafinilThe serum concentration of Buprenorphine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Buprenorphine.
MorphineBuprenorphine may decrease the analgesic activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Buprenorphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buprenorphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Buprenorphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
NabiloneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Buprenorphine.
NafcillinThe serum concentration of Buprenorphine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Buprenorphine.
NaloxegolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Naloxegol.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Buprenorphine.
NaltrexoneThe therapeutic efficacy of Buprenorphine can be decreased when used in combination with Naltrexone.
NefazodoneThe metabolism of Buprenorphine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Buprenorphine can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Buprenorphine.
NetupitantThe serum concentration of Buprenorphine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Buprenorphine can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nialamide.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Buprenorphine.
NicardipineThe metabolism of Buprenorphine can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Buprenorphine.
NilotinibThe metabolism of Buprenorphine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Buprenorphine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Buprenorphine.
NitrazepamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Buprenorphine.
NormethadoneBuprenorphine may decrease the analgesic activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Buprenorphine.
NortriptylineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Buprenorphine.
OctamoxinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Octamoxin.
OlanzapineBuprenorphine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Buprenorphine.
OlaparibThe metabolism of Buprenorphine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Buprenorphine.
OmeprazoleThe metabolism of Buprenorphine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Buprenorphine.
OpiumBuprenorphine may decrease the analgesic activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Buprenorphine.
OrphenadrineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Buprenorphine.
OsanetantThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Osanetant.
OsimertinibThe serum concentration of Buprenorphine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Buprenorphine.
OxprenololThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Buprenorphine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine.
OxycodoneBuprenorphine may decrease the analgesic activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Buprenorphine.
OxymorphoneBuprenorphine may decrease the analgesic activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Buprenorphine.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Buprenorphine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Buprenorphine.
PalbociclibThe serum concentration of Buprenorphine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Buprenorphine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Buprenorphine.
PanobinostatThe metabolism of Buprenorphine can be decreased when combined with Panobinostat.
ParaldehydeBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Buprenorphine.
PargylineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pargyline.
ParoxetineBuprenorphine may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Buprenorphine can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Buprenorphine.
Peginterferon alfa-2bThe serum concentration of Buprenorphine can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Buprenorphine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Buprenorphine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Buprenorphine.
PerampanelThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Buprenorphine.
PerphenazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Perphenazine.
PethidineBuprenorphine may decrease the analgesic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Buprenorphine.
PhenelzineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenelzine.
PheniprazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pheniprazine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Buprenorphine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Buprenorphine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenoxypropazine.
PhenterminePhentermine may increase the analgesic activities of Buprenorphine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Buprenorphine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Buprenorphine.
PimozideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pimozide.
PioglitazoneThe metabolism of Buprenorphine can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Buprenorphine.
PipotiazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Buprenorphine.
PiretanideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Piretanide.
PirlindoleThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pirlindole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Buprenorphine.
PivhydrazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Buprenorphine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Buprenorphine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Buprenorphine.
PosaconazoleThe metabolism of Buprenorphine can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium Citrate.
PramipexoleBuprenorphine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Buprenorphine.
PrazepamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Buprenorphine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Buprenorphine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Buprenorphine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Buprenorphine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Buprenorphine.
PrimidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Buprenorphine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Buprenorphine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Buprenorphine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Buprenorphine.
PromazinePromazine may increase the hypotensive activities of Buprenorphine.
PromazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Buprenorphine.
PromethazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Buprenorphine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Buprenorphine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Buprenorphine.
PropoxycaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Buprenorphine.
ProtriptylineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Buprenorphine.
PSD502The risk or severity of adverse effects can be increased when Buprenorphine is combined with PSD502.
PyrimethamineThe metabolism of Buprenorphine can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Buprenorphine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Buprenorphine.
QuinethazoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Buprenorphine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Buprenorphine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Buprenorphine.
QuinineThe metabolism of Buprenorphine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Buprenorphine can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ramelteon.
RamosetronBuprenorphine may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Buprenorphine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Buprenorphine.
RanolazineThe metabolism of Buprenorphine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Rasagiline.
RemifentanilBuprenorphine may decrease the analgesic activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Buprenorphine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Buprenorphine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Buprenorphine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Buprenorphine.
RifabutinThe metabolism of Buprenorphine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Buprenorphine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Buprenorphine.
RifapentineThe metabolism of Buprenorphine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Buprenorphine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Buprenorphine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Buprenorphine.
RitonavirThe metabolism of Buprenorphine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Buprenorphine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Buprenorphine.
RolapitantThe metabolism of Buprenorphine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Buprenorphine.
RomifidineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Romifidine.
RopiniroleBuprenorphine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Buprenorphine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Buprenorphine.
RosiglitazoneThe metabolism of Buprenorphine can be decreased when combined with Rosiglitazone.
RotigotineBuprenorphine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Buprenorphine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Buprenorphine is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Safrazine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Buprenorphine.
SaquinavirThe metabolism of Buprenorphine can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Buprenorphine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Buprenorphine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Buprenorphine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Buprenorphine.
SelegilineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Buprenorphine.
SertindoleThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Sertindole.
SertralineBuprenorphine may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Buprenorphine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Sevoflurane.
SildenafilThe metabolism of Buprenorphine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Buprenorphine.
SiltuximabThe serum concentration of Buprenorphine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Buprenorphine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Buprenorphine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Buprenorphine.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Buprenorphine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Buprenorphine.
SorafenibThe metabolism of Buprenorphine can be decreased when combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Buprenorphine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Buprenorphine.
SpironolactoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Spironolactone.
St. John's WortThe serum concentration of Buprenorphine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Buprenorphine.
SufentanilBuprenorphine may decrease the analgesic activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Buprenorphine.
SulfadiazineThe metabolism of Buprenorphine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Buprenorphine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Buprenorphine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Buprenorphine.
SuvorexantThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Buprenorphine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Buprenorphine.
TamoxifenThe metabolism of Buprenorphine can be decreased when combined with Tamoxifen.
TapentadolBuprenorphine may decrease the analgesic activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Buprenorphine.
TasimelteonThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Buprenorphine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Buprenorphine.
TelaprevirThe metabolism of Buprenorphine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Buprenorphine.
TelithromycinThe metabolism of Buprenorphine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Buprenorphine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Buprenorphine.
TerbinafineThe metabolism of Buprenorphine can be decreased when combined with Terbinafine.
TeriflunomideThe metabolism of Buprenorphine can be decreased when combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tetrodotoxin.
ThalidomideBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Buprenorphine.
TheobromineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Buprenorphine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Buprenorphine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Buprenorphine.
ThioridazineThioridazine may increase the hypotensive activities of Buprenorphine.
ThiothixeneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Buprenorphine.
TicagrelorThe metabolism of Buprenorphine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Buprenorphine can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Buprenorphine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Buprenorphine.
TipranavirThe metabolism of Buprenorphine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tizanidine.
TocilizumabThe serum concentration of Buprenorphine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Buprenorphine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tolcapone.
ToloxatoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Toloxatone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Buprenorphine.
TolvaptanThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Buprenorphine.
TorasemideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Buprenorphine.
TramadolBuprenorphine may decrease the analgesic activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Buprenorphine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tranylcypromine.
TranylcypromineThe metabolism of Buprenorphine can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Buprenorphine.
TrazodoneBuprenorphine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Buprenorphine.
TriamtereneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Buprenorphine.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Buprenorphine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Buprenorphine.
TriflupromazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Buprenorphine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Buprenorphine.
TrimethoprimThe metabolism of Buprenorphine can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Buprenorphine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Buprenorphine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Buprenorphine.
UlaritideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ularitide.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Buprenorphine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Buprenorphine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Buprenorphine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Buprenorphine.
ValsartanThe metabolism of Buprenorphine can be decreased when combined with Valsartan.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Buprenorphine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Buprenorphine.
VenlafaxineThe metabolism of Buprenorphine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Buprenorphine.
VerapamilThe metabolism of Buprenorphine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Buprenorphine.
VigabatrinThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Vigabatrin.
VilazodoneBuprenorphine may increase the serotonergic activities of Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Buprenorphine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Buprenorphine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Buprenorphine.
VoriconazoleThe metabolism of Buprenorphine can be decreased when combined with Voriconazole.
VortioxetineBuprenorphine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Buprenorphine.
XylazineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Xylazine.
ZafirlukastThe metabolism of Buprenorphine can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Buprenorphine.
ZimelidineBuprenorphine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Buprenorphine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Buprenorphine.
ZonisamideThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Kishioka S, Paronis CA, Lewis JW, Woods JH: Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. Eur J Pharmacol. 2000 Mar 17;391(3):289-97. [PubMed:10729371 ]
  2. Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, Koeppe RA, Schuster CR, Johanson CE: Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 2000 Sep;23(3):326-34. [PubMed:10942856 ]
  3. Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J: Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull. 2001 Jan 15;54(2):229-35. [PubMed:11275413 ]
  4. Mizoguchi H, Wu HE, Narita M, Hall FS, Sora I, Uhl GR, Nagase H, Tseng LF: Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse. Neuroscience. 2002;115(3):715-21. [PubMed:12435410 ]
  5. Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K: Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology. 2004 Sep;29(9):1656-63. [PubMed:15100703 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Boothby LA, Doering PL: Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm. 2007 Feb 1;64(3):266-72. [PubMed:17244875 ]
  2. Robinson SE: Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs. 2006;20(9):697-712. [PubMed:16953647 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Induru RR, Davis MP: Buprenorphine for neuropathic pain--targeting hyperalgesia. Am J Hosp Palliat Care. 2009 Dec-2010 Jan;26(6):470-3. doi: 10.1177/1049909109341868. Epub 2009 Aug 7. [PubMed:19666890 ]
  2. Lester PA, Traynor JR: Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res. 2006 Feb 16;1073-1074:290-6. Epub 2006 Jan 27. [PubMed:16443205 ]
  3. Megarbane B, Marie N, Pirnay S, Borron SW, Gueye PN, Risede P, Monier C, Noble F, Baud FJ: Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol. 2006 May 1;212(3):256-67. Epub 2005 Sep 16. [PubMed:16169027 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y: Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998 Aug;26(8):818-21. [PubMed:9698298 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4. [PubMed:19887017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4. [PubMed:19887017 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 01, 2016 02:31